Chemomab Therapeutics (CMMB) has released an update.
Chemomab Therapeutics Ltd. has released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2024. The statements show a decrease in total current assets from the previous year-end, with figures moving from $20,897 thousand to $13,455 thousand. The report also details changes in liabilities, including trade payables and accrued expenses.
For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.
